TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03878563

Intervention type: DEVICE
Intervention: Cellvisio 100 Series (fibered confocal microscopic system)
Description: This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Intervention type: DEVICE
Intervention: Cellvisio 100 Series (fibered confocal microscopic system)
Description: This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Intervention type: DEVICE
Intervention: Cellvisio 100 Series (fibered confocal microscopic system)
Description: This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Intervention type: DEVICE
Intervention: Cellvisio 100 Series (fibered confocal microscopic system)
Description: This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.

Intervention type: DEVICE
Intervention: Cellvisio 100 Series (fibered confocal microscopic system)
Description: This system is intended to allow confocal laser imaging of the internal microstructure of tissues within or adjacent to anatomical tracts, i.e. Gastrointestinal accessed trough an endoscope.~An 488-nm wavelength laser system is used, images are steamed at a frame rate of 12 frames per second, obtaining real time videos of the mucosa. In this trial we will use the Confocal miniprobe ColoFlex UHD and GastroFlex UHD.
Study: NCT02351622

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Caffeic acid
Description: Oral administration of caffeic acid tablet 0.3g three times per day for 1 year

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Oral administration of dexamethasone 40 mg for four consecutive days then proceed another cycle 10 days later, 3 cycles in total.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Sugar pills manufactured to mimic caffeic acid tablet. Oral administration of placebo tablet 0.3g three times per day for 1 year.
Study: NCT02695108

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: classical approach for neck pain
Description: Patients with mechanical neck pain were instructed to do cervical exercise

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: scapular exercise on neck pain
Description: Patients with mechanical neck pain were instructed to do scapular stabilization and cervical exercise
Study: NCT02851615

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: SCThrive Intervention for Adolescents with SCD
Description: Chronic Disease Self-Management Program
Study: NCT03510546

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyridostigmine
Description: Study dose as per protocol.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Study dose as per protocol.
Study: NCT04697771

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fine Motor Skills Training
Description: The fine motor skills training program was planned for the areas of difficulty that children with ADHD experience in the fine motor area as stated in the literature (Lavasani \& Stagnitti, 2011). The fine motor goals were organized for 8 weeks, each week including a different fine motor area and practicing handwriting. For each fine motor goal, 3 different activities were identified that did not require materials or could be practiced with materials that could be easily found in each child's home. For example, for the fine motor strengthening goal, three different activities were planned for the same purpose with tools such as play dough, nails, and staples (Case-Smith \& O'Brien, 2013). The activities determined each week were repeated three days a week in the same way and applied to all children. Within the 40-minute session, each activity was performed for 10 minutes under the guidance of an expert occupational therapist.
Study: NCT00702351

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286 (corifollitropin alfa)
Description: A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Org 36286 (corifollitropin alfa)
Description: A single dose of Org 36286 will be administered after down-regulation has been confirmed (E2 below 50 ng/L and P below 1.48 μg/L). The first group comprising subjects weighing \>= 50 kg will receive a dose of 150 μg Org 36286 (150 μg dose group). The second group comprising subjects weighing \<= 60 kg will receive a dose of 100 μg Org 36286 (100 μg dose group).
Study: NCT00156819

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: fluticasone
Description: fluticasone (100 microgram twice daily) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: fluticasone (100 microgram twice daily) treatment

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluticasone
Description: fluticasone (100 microgram twice daily) treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: montelukast
Description: Montelukast (5 or 10 mg each night).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: Montelukast (5 or 10 mg each night).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: montelukast
Description: Montelukast (5 or 10 mg each night).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone plus salmeterol
Description: fluticasone (100 microgram) plus salmeterol (50 microgram) each night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone plus salmeterol
Description: fluticasone (100 microgram) plus salmeterol (50 microgram) each night

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone plus salmeterol
Description: fluticasone (100 microgram) plus salmeterol (50 microgram) each night
Study: NCT04533568

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: 400mg intravenous ibuprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexketoprofen
Description: 50 mg intravenous dexketoprofen with 10mg intravenous metoclopramide Hcl in 100ml 0.9% NaCl for 30 minutes.
Study: NCT02787889

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Uneven Protein intake pattern
Description: Each participant will consume 15%/2-%/65% of total protein in breakfast, lunch, and dinner, respectively)\] on net protein synthesis over 8 weeks.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Even Protein Intake Pattern
Description: Each participant will consume 33% of total protein consumed each meal
Study: NCT02966301

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arsenic Trioxide Injectable Solution
Description: Each patient will receive eleven perfusions of arsenic trioxide (0,15 mg/kg/Day - IV administration) over a 4 weeks period (one cycle).~Patients in partial response after the 1st cycle of ATO will be eligible to receive a second cycle of ATO as consolidation therapy. A delay of 8 weeks (from the first infusion of ATO) will be observed between the two cycles of ATO therapy.~The study duration will be 2 years (12 months recruitment + 12 months follow-up).
Study: NCT01431222

Intervention type: DEVICE
Group type: NO_INTERVENTION
Intervention: percutaneous treatment by implanting a Mitra Clip device
Description: With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: percutaneous treatment by implanting a Mitra Clip device
Description: With a minimal-invasive, percutaneous catheter-based technique and trans-septal approach under transesophageal echocardiographic and fluoroscopic guidance, the MitraClip device grasps and approximates the mitral leaflets thus creating a double-orifice mitral valve with a permanent leaflet coaptation and a reduction or even abrogation of mitral regurgitation.
Study: NCT02349646

Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study: NCT00448279

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: 2mg/kg i.v. weekly, or 6mg/kg i.v. every 3 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Schedule and dose at the investigator's discretion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Description: Schedule and dose at the investigator's discretion
Study: NCT01666379

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Study: NCT00889668

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GlucoTrack
Description: comparison of different glucose monitoring devices
Study: NCT00642772

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Group Physical Therapy
Description: 12-week group-based program of physical therapy. Participants will meet approximately every other week for a total of 6 visits. The group sessions will include education about appropriate self-care for knee osteoarthritis and instructions and participation in group exercises. Participants will also be instructed in a home exercise program.
Study: NCT01600820

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1- Low fat drinkable fermented dairy product enriched with 1.6g of plant sterol (as free equivalent) per unit
Description: 1 = Intervention 1 (1 test product/day)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 2- Low fat drinkable fermented dairy product enriched with 2.0g of plant sterol (as free equivalent) per unit
Description: 2 = Intervention 2 (1 test product/day)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: 3- Low fat drinkable fermented dairy product without plant sterols(control)
Description: 3 = Intervention 3 (1 control product/day)
Study: NCT03127254

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video narrative
Description: create a 10-15 minute video intervention about teen experiences after being diagnosed with cancer

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PedsQL
Description: A generic 23-item Health Related Quality of Life measure initially developed using pediatric cancer patients

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ten Item Personality Inventory
Description: The TIPI consists of ten items and measures personality based the subject's agreement of descriptions of themselves taken from the Big-5 model of personality

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delis-Kaplan Executive Function System (D-KEFS) Verbal Fluency Test
Description: The D-KEFS Verbal Fluency Test consists of three subtests, which take approximately 6 minutes to complete

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Cognitive Log
Description: The Cog-Log is a 5-10 minute assessment designed to measure basic cognitive functioning and orientation
Study: NCT02937454

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ferric carboxymaltose
Description: FCM will be administered as an undiluted bolus injection. The study treatment dose (mL) to be administered will be determined by the patient's body weight and haemoglobin (Hb) value at the respective visits where study treatment will be administered

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline 0.9%
Description: Normal saline will be administered as a bolus injection.
Study: NCT02116101

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Bright Momchilovtsi Yogurt
Description: Oral consumption of Bright Momchilovtis Yogurt containing 1×106cfu/g prebiotics including Lactobacillus bulgaricus and Streptococcus thermophilus~Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Bright Dairy Beverage
Description: Oral consumption of Bright Dairy Beverage Dosage: 110g at a time, twice per day at 10 am and 4 pm. Duration: 7 weeks (March 10, 2013 - April 27, 2013) The active study product has similar package and taste as the placebo.
Study: NCT04417296

Intervention type: DIAGNOSTIC_TEST
Intervention: antepartum computerised cardiotocography analysis
Description: A common obstetric methodical to evaluate the fetal well-being is the antepartum fetal heart rate (FHR) monitoring through cardiotocography (CTG)
Study: NCT02184650

Intervention type: OTHER
Intervention: Premature infants with a GA < 32 weeks
Description: At 3 years of age: ASQ (filled in by parents)
Study: NCT02999126

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol intravenously by a stepwise TCI titration with Marsh pharmacokinetic model

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Hydrochloride
Description: Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Remifentanil Hydrochloride
Description: Remifentanil intravenously 6 ng/ml by TCI effect site, 3 min prior to intubation and maintained at that concentration throughout the study. If clinical signs of inadequate analgesia are present, remifentanil target concentration will be increased by 1 ng/ml.
Study: NCT03542461

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: 240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.

Intervention type: DRUG
Group type: OTHER
Intervention: Nivolumab 10 MG/ML Intravenous Solution
Description: 240 mg as a 30 minutes IV infusion on Day 1 of each treatment cycle every 2 weeks, until intolerable toxicity or patient refusal or investigator's decision. In case of disease progression the treatment should be discontinued unless documented clinical benefits in the Investigator's judgement (no rapid progression, tolerance of trial drug, stable performance status, treatment maintenance does not delay an imminent intervention to prevent serious complication of PD) and no evidence of further progression at a radiographic assessment performed within 6 weeks. No dose escalations or reduction allowed. Administration delay until 6 weeks as well as resuming dose are allowed according to protocol defined criteria.

Intervention type: OTHER
Group type: OTHER
Intervention: Best Supportive Care
Description: Care that aims to optimize the comfort, function and social support of the patients and their family at all stages of the illness. Best Supportive Care (BSC)includes the use of analgesics, antibiotics, blood tranfusions, blood products, radiotherapy, corticosteroids, antiemetics, antidiarrheals, vitamins and any intervention aiming the improvement of patient's discomfort. Any chemotherapy, immunotherapy and targeted therapy are not considered as part of BSC.
Study: NCT00559702

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: natalizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: natalizumab
Description: natalizumab

Intervention type: OTHER
Group type: OTHER
Intervention: standard of care
Description: standard of care as determined by the Investigator and Treating Neurologist
Study: NCT03843931

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: GLA:D
Description: The GLA:D exercise and education program is an 8-week treatment program delivered by GLA:D certified physiotherapists. It consists of 2 educational sessions over 2 weeks (1/week in week 1 and 2) and 12 exercise sessions over 6 weeks (2/week in weeks 2 thru 8) The 2 educational sessions provide knowledge of OA, treatment and self-management, with a special focus on exercise and its benefits. The exercise part lasts for 6 weeks with 2 exercise sessions per week of approximately 1 hour (12 sessions total). The exercise sessions are group based at a facility supervised by a GLA:D certified physiotherapist. The goal is the obtain muscle control and stability in situations resembling daily life and/or more strenuous activities.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Intra-articular saline injection
Description: Four \[4\] dosages of 5 ml intra-articular isotonic saline (0.9% (9 mg/mL) Sodium Chloride Injection (sterile, isotonic solution of sodium chloride and sterile water for injection)) every other week from baseline (week 1, 3, 5 and 7 = 4 injections).~The injections will be carried out with a 21 gauge (38 mm) needle and a Luer-lock syringe under ultrasound guidance to ensure that the needle is inserted into the study knee joint cavity and document correct deposition of the bolus in the joint cavity.~If the investigator detects presence of excessive joint fluid during the ultrasound guided preparation of the injection, this will be aspirated before injection of the saline - if possible.
Study: NCT02344563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Meropem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Meropem

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mepem

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mepem
Study: NCT01176279

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Manual and automated washing of the peripherical lines
Description: The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~Obtain 2cc of blood using the arterial blood sampling syringe connected to the proximal key. This volume of rejection is reserved in the syringe itself.~In accordance with the current protocol of disinfection, the needless connector inserted on the distal key will be disinfected. With a disposable sterile syringe the needless connector is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved is returned to the bloodstream. This arterial blood sampling syringe is cleaned aspirating serum manually in order to wash the line.~Additional line washing is made through the fast flow valve of the system BD DTXPlus ™.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Automated washing of the peripherical lines
Description: The extractions of the blood for the analysis of the glycaemia will be made puncturing the needless connector inserted in the distal 3-way stopcock key once an hour during 48 hours.~In accordance with the current protocol of disinfection, the two needless connectors inserted on the two 3-way stopcock keys will be disinfected.~With a disposable sterile syringe the needless connector on proximal 3-way stopcock is punctured and 2cc of blood are aspirated. This volume of rejection is reserved in the syringe itself and it is not disconnected.~With a second disposable sterile syringe the needless connector on distal 3-way stopcock key is punctured and a minimum blood amount is obtained for the determination of the glycaemia.~Once the sample has been obtained, the rejection volume reserved in the disposable syringe connected to the proximal 3-way stopcock is returned to the bloodstream.~Line washing will be made through the fast flow valve of the system BD DTXPlus ™.
Study: NCT01774487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pentoxifylline
Description: 20 mg/kg/day divided in 3 doses, given orally for 90 days
Study: NCT03058835

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tenofovir disoproxil and emtricitabine
Description: Pre-exposure Prophylaxis with Truvada will be distributed to all participants eligible to receive PrEP.
Study: NCT00346632

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KW-2449
Description: Sequential ascending oral doses of KW-2449 given for 14 or 28 days (modified by protocol amendment to only 14 days dosing).